Assessing the Degree of Patient-Physician Agreement on Perceived Disease Burden in Generalised Myasthenia Gravis: A European Study

Generalised myasthenia gravis (gMG) significantly affects physical functioning and emotional wellbeing. Many patients with gMG report a disconnect between their lived experience and physicians’ perceptions of disease impact, which may impact treatment priorities and shared decision-making. We assessed patient-physician concordance on perceived gMG burden and explored factors contributing to perceptual gaps. Across five European countries (France, Germany, Italy, Spain, UK), 167 adult patients with gMG and their treating physicians (n = 24) independently completed online surveys assessing the perceived impact of gMG on physical functioning and emotional wellbeing, using 0–100 visual analogue scales (VAS). Discordance was defined as an absolute VAS score difference of ≥ 20 points. Additionally, 25 patients and 25 physicians participated in semi-structured qualitative interviews exploring lived experiences, consultation dynamics, and treatment decision-making. VAS score agreement was assessed using intraclass correlation coefficient (ICC) and Bland-Altman analysis; qualitative interviews were analysed thematically. Overall, mean patient and physician VAS scores were similar for physical functioning (57.9 vs 59.6, p = 0.20) and emotional wellbeing (58.7 vs 61.0, p = 0.09), with "substantial" concordance in 81% of patient-physician pairs (ICC: ~ 0.7). Conversely, 19% of patient-physician pairs demonstrated clear discordance, with physicians either over- or underestimating burden. Notably, even among concordant pairs, up to one fifth reported score differences approaching the discordance threshold, reflecting subtle, but potentially meaningful, misalignment. Qualitative insights suggested that short consultations, under-recognition of fluctuating symptoms, and blind spots regarding psychosocial impacts may contribute to perceptual gaps. Despite overall broad patient-physician concordance of VAS scores, meaningful misalignment in perceived gMG burden persists. Qualitative insights highlighted perceptual gaps that may be driven by limited consultation time and under-addressed psychosocial needs. Incorporating structured, symptom-focused dialogue alongside standard assessments may improve recognition of disease burden and support patient-centred gMG management. Symptoms of generalised myasthenia gravis (gMG) can change daily and may affect education, work, social activities, travel, relationships, and emotional wellbeing. This study explored whether people with gMG and their doctors had similar views about gMG's impact. Researchers surveyed 167 people with gMG and their doctors across five European countries. Patients and doctors independently rated the impact of gMG on physical functioning and emotional wellbeing using a 0–100 scoring system, known as the visual analogue scale (VAS). Researchers also interviewed 25 patients and 25 doctors about their perspectives. Most patients and doctors gave similar VAS scores, suggesting a broadly shared understanding of gMG's impact. However, there were still small, but potentially meaningful, score differences, suggesting differences in perception that could be missed during an appointment. A larger gap was seen in almost a fifth of patient-doctor pairs. These pairs had VAS score differences of 20 points or more, meaning their perceptions of disease burden differed substantially. Doctors underestimated impact more often than they overestimated it. The interviews helped explain why these perception gaps may occur. Patients described challenges that were not always discussed during appointments, including fluctuating symptoms and the emotional and social effects of gMG. Doctors recognised these issues but said limited consultation time and assessment approaches make them difficult to capture. These findings highlight the importance of open conversations between patients and doctors to ensure that patients are heard and the full impact of gMG is recognised when making treatment decisions.

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2026-11-15
DOI
https://doi.org/10.1007/s40120-026-01065-0
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Assessing the Degree of Patient-Physician Agreement on Perceived Disease Burden in Generalised Myasthenia Gravis: A European Study

Lauren Halliwell, Sophie Lehnerer, Elise Roche, Alisa Matei
Neurology and Therapy
Myasthenia Gravis and Thymoma
article

Assessing the Degree of Patient-Physician Agreement on Perceived Disease Burden in Generalised Myasthenia Gravis: A European Study

Lauren Halliwell, Sophie Lehnerer, Elise Roche, Alisa Matei
article en

Abstract

Generalised myasthenia gravis (gMG) significantly affects physical functioning and emotional wellbeing. Many patients with gMG report a disconnect between their lived experience and physicians’ perceptions of disease impact, which may impact treatment priorities and shared decision-making. We assessed patient-physician concordance on perceived gMG burden and explored factors contributing to perceptual gaps. Across five European countries (France, Germany, Italy, Spain, UK), 167 adult patients with gMG and their treating physicians (n = 24) independently completed online surveys assessing the perceived impact of gMG on physical functioning and emotional wellbeing, using 0–100 visual analogue scales (VAS). Discordance was defined as an absolute VAS score difference of ≥ 20 points. Additionally, 25 patients and 25 physicians participated in semi-structured qualitative interviews exploring lived experiences, consultation dynamics, and treatment decision-making. VAS score agreement was assessed using intraclass correlation coefficient (ICC) and Bland-Altman analysis; qualitative interviews were analysed thematically. Overall, mean patient and physician VAS scores were similar for physical functioning (57.9 vs 59.6, p = 0.20) and emotional wellbeing (58.7 vs 61.0, p = 0.09), with "substantial" concordance in 81% of patient-physician pairs (ICC: ~ 0.7). Conversely, 19% of patient-physician pairs demonstrated clear discordance, with physicians either over- or underestimating burden. Notably, even among concordant pairs, up to one fifth reported score differences approaching the discordance threshold, reflecting subtle, but potentially meaningful, misalignment. Qualitative insights suggested that short consultations, under-recognition of fluctuating symptoms, and blind spots regarding psychosocial impacts may contribute to perceptual gaps. Despite overall broad patient-physician concordance of VAS scores, meaningful misalignment in perceived gMG burden persists. Qualitative insights highlighted perceptual gaps that may be driven by limited consultation time and under-addressed psychosocial needs. Incorporating structured, symptom-focused dialogue alongside standard assessments may improve recognition of disease burden and support patient-centred gMG management. Symptoms of generalised myasthenia gravis (gMG) can change daily and may affect education, work, social activities, travel, relationships, and emotional wellbeing. This study explored whether people with gMG and their doctors had similar views about gMG's impact. Researchers surveyed 167 people with gMG and their doctors across five European countries. Patients and doctors independently rated the impact of gMG on physical functioning and emotional wellbeing using a 0–100 scoring system, known as the visual analogue scale (VAS). Researchers also interviewed 25 patients and 25 doctors about their perspectives. Most patients and doctors gave similar VAS scores, suggesting a broadly shared understanding of gMG's impact. However, there were still small, but potentially meaningful, score differences, suggesting differences in perception that could be missed during an appointment. A larger gap was seen in almost a fifth of patient-doctor pairs. These pairs had VAS score differences of 20 points or more, meaning their perceptions of disease burden differed substantially. Doctors underestimated impact more often than they overestimated it. The interviews helped explain why these perception gaps may occur. Patients described challenges that were not always discussed during appointments, including fluctuating symptoms and the emotional and social effects of gMG. Doctors recognised these issues but said limited consultation time and assessment approaches make them difficult to capture. These findings highlight the importance of open conversations between patients and doctors to ensure that patients are heard and the full impact of gMG is recognised when making treatment decisions.

Neurology and Therapy
Humboldt-Universität zu Berlin (DE), UCB Pharma (United Kingdom) (GB), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon